

EBOOK

Biologics Manufacturing Across APAC 2026 - 2027

Facilities & Capabilities Landscape

Mapping Capacity. Enabling Growth.
Powering the Future of Biologics.



STATE OF FACILITIES



CAPABILITIES
ANALYSIS



INVESTMENT
TRENDS



STRATEGIC
OUTLOOK

About this report

Asia-Pacific has emerged as a major global hub for biologics manufacturing, supported by increasing demand for biologics and biosimilars, expansion of CDMO and CRDMO capacity, regionalisation of supply chains and continued investment in commercial-scale manufacturing infrastructure.

The region combines established manufacturing clusters such as South Korea, China, Japan and Singapore with rapidly expanding capabilities in India, Taiwan, Australia and Malaysia.

This infographic provides an overview of key biologics manufacturing organisations and their major manufacturing footprints across APAC, bringing together end-user biopharma manufacturers, vaccine manufacturers and CDMO/CRDMO providers. Where companies operate multiple facilities within a country, these have been consolidated into a single entry to provide a clearer view of the overall manufacturing landscape.

Methodology. Facilities are grouped by company within each country rather than listing every individual plant. Capacity is included only where publicly disclosed and should not be directly compared where companies use different capacity definitions.

HOW TO READ THE TABLES

End-user 29 entries
 CDMO / CRDMO 20 entries
 Vaccine / Biologics 14 entries
Other 2 entries

COVERAGE BY MARKET



What is inside

About this report	Scope and methodology	2
	SINGAPORE 10 entries	4
	MALAYSIA 5 entries	5
	SOUTH KOREA 8 entries	6
	JAPAN 8 entries	7
	CHINA 10 entries	8
	TAIWAN 6 entries	9
	INDIA 12 entries	10
	AUSTRALIA 6 entries	11
Where APAC goes next	Outlook	12
Biologics Manufacturing Asia 2027	Join us in Singapore	13

01 SINGAPORE

10 ENTRIES

Singapore is a major APAC manufacturing hub for multinational pharmaceutical companies and CDMOs, with Tuas Biomedical Park as the key concentration.

COMPANY	MAJOR SITES / MANUFACTURING HUBS	MANUFACTURING TYPE	KEY CAPABILITIES
Lonza Specialized Modalities	Tuas	CDMO	Mammalian biologics, mAbs, recombinant proteins
AMGEN	Tuas	END-USER	Biologics DS / advanced manufacturing
abbvie	Tuas	END-USER	Biologics DS
sanofi	Tuas – Modulus	END-USER	Vaccines / biologics
GSK	Tuas	VACCINE / BIOLOGICS	Vaccines
WuXi Biologics Global Solution Provider	Singapore	CRDMO	Biologics DS/DP
XDC The Bioconjugation Leader	Tuas	CDMO	Bioconjugates / ADC manufacturing
BIONTECH	Singapore	END-USER	mRNA manufacturing
Pfizer	Singapore	END-USER	Biopharmaceutical manufacturing
NOVARTIS	Singapore	END-USER	Biologics / pharmaceutical manufacturing

CAPABILITY MIX

● End-user 6 ● CDMO / CRDMO 3 ● Vaccine / Biologics 1

02 MALAYSIA

5 ENTRIES

Malaysia is developing a stronger biologics manufacturing base, particularly around Johor, with capabilities in insulin, biosimilars, vaccine fill-finish and pharmaceutical manufacturing.

COMPANY	MAJOR SITES / MANUFACTURING HUBS	MANUFACTURING TYPE	KEY CAPABILITIES
 Biocon	Johor	END-USER	Insulin DS/DP, biosimilars, sterile injectables
 pharmaniaga®	Puchong	VACCINE / BIOLOGICS	Vaccine fill-finish
 DUOPHARMA	Malaysia	END-USER	Biosimilars / biologics
 BioCare <i>Transforming Healthcare</i>	Malaysia	END-USER	Biologics / sterile manufacturing
 ccm	Malaysia	PHARMACEUTICAL / VACCINE	Vaccine / sterile products

CAPABILITY MIX

● End-user 3

● Vaccine / Biologics 2



03



SOUTH KOREA

8 ENTRIES

South Korea's biologics manufacturing ecosystem is heavily concentrated around Songdo/Incheon, alongside established vaccine and biologics facilities in Andong, Pyeongtaek and Hwasun.

COMPANY	MAJOR SITES / MANUFACTURING HUBS	MANUFACTURING TYPE	KEY CAPABILITIES
SAMSUNG BIOLOGICS	Songdo / Incheon – Plants 1–5	CDMO	Mammalian biologics, drug substance, drug product, aseptic fill-finish
 CELLTRION	Songdo / Incheon – Plants 1–3; Plants 4–5	END-USER	Monoclonal antibodies, biosimilars, biologics DS
 LOTTE BIOLOGICS	Songdo	CDMO	Mammalian biologics, DS/DP
 SK bioscience	Andong – L HOUSE	VACCINE / BIOLOGICS	Cell-culture, bacterial, viral and recombinant vaccines
 GC Biopharma	Hwasun	VACCINE / BIOLOGICS	Vaccines, plasma-derived products, biologics
 Hanmi	Pyeongtaek	END-USER / BIOLOGICS	Microbial biologics, recombinant proteins
 LG Chem	Osong / Iksan	END-USER	Vaccines / biological products
BORYUNG Biopharma	Daejeon	VACCINE / BIOLOGICS	Vaccines and biological products

Note. Samsung's 845 kL figure is global, not APAC-only; its current Korean Plants 1–5 total 784 kL.

CAPABILITY MIX

End-user 3

CDMO / CRDMO 2

Vaccine / Biologics 3

04 JAPAN

8 ENTRIES

Japan has an established biologics manufacturing base spanning innovative biopharma, vaccines and specialist CDMO capabilities.

COMPANY	MAJOR SITES / MANUFACTURING HUBS	MANUFACTURING TYPE	KEY CAPABILITIES
 CHUGAI	Utsunomiya, Ukima / Tokyo	END-USER	Antibody DS, biologics
 AGC Biologics Right. On Time.	Chiba	CDMO	Mammalian & microbial biologics
 Takeda Better Health, Brighter Future	Hikari	END-USER	Biologics, vaccines, plasma products
 KYOWA KIRIN	Takasaki	END-USER	Biopharmaceuticals
 FUJIFILM	Japan	CDMO	Biologics / advanced therapies
 Ajinomoto BIO-PHARMA SERVICES	Japan	CDMO	Biologics / sterile manufacturing
 Daiichi-Sankyo	Japan	END-USER	Antibodies / biologics
 astellas	Japan	END-USER	Biologics / sterile products

CAPABILITY MIX

● End-user 5

● CDMO / CRDMO 3

05 CHINA

10 ENTRIES

China has one of the deepest biologics manufacturing ecosystems in APAC, combining domestic biopharma manufacturers with large-scale CRDMOs. To avoid WuXi dominating the table, its numerous sites are consolidated into one regional footprint.

COMPANY	MAJOR SITES / MANUFACTURING HUBS	MANUFACTURING TYPE	KEY CAPABILITIES
 WuXi Biologics Global Solution Provider	Wuxi, Shanghai, Suzhou, Hangzhou, Chengdu, Shijiazhuang	CRDMO	Mammalian & microbial DS/DP, commercial biologics
 Innovent	Suzhou, Hangzhou	END-USER / MANUFACTURING	mAbs, biosimilars, biologics
 Henlius	Shanghai – Xuhui & Songjiang	END-USER	mAbs, biosimilars
 BeiGene	Guangzhou, Suzhou	END-USER	mAbs, bispecifics, recombinant proteins
 三生制药 3SBIO INC.	Shenyang, Shanghai, Shenzhen	END-USER	Recombinant proteins, mAbs
 康希诺生物 CanSinoBIO	Tianjin	VACCINE / BIOLOGICS	Viral-vector and recombinant vaccines
FOSUN PHARMA	Shanghai / multiple China sites	END-USER	Biologics, vaccines, biosimilars
 Henlius	Shanghai	END-USER	Monoclonal antibodies / biosimilars
 康龙化成 PHARMARON	Ningbo, China	CDMO	Biologics manufacturing
Biologics / vaccine manufacturing clusters	Shanghai, Wuxi, Suzhou, Hangzhou, Guangzhou, Chengdu	MULTIPLE	DS, DP, vaccines, mAbs, biosimilars

Note. WuXi is particularly important to capture as one company with a multi-city manufacturing footprint. Its Shanghai Fengxian MFG17 facility completed its first GMP production campaign in June 2026, becoming its 25th drug-substance manufacturing facility globally

CAPABILITY MIX

● End-user 6 ● CDMO / CRDMO 2 ● Vaccine / Biologics 1 ● Other 1

06 TAIWAN

6 ENTRIES

Taiwan's biologics manufacturing ecosystem is smaller than Korea, China or Japan but has growing capabilities in biologics CDMO, microbial fermentation and mammalian cell culture.

COMPANY	MAJOR SITES / MANUFACTURING HUBS	MANUFACTURING TYPE	KEY CAPABILITIES
 Bora Biologics	Zhubei / Hsinchu	CDMO	Mammalian & microbial biologics
 Bora Pharmaceuticals	Taiwan	CDMO / END-USER	Sterile / pharmaceutical manufacturing
 MYCENAX	Taiwan	CDMO / END-USER	Biologics / biosimilars
 PharmaEssentia Better Science . Better Lives.	Taiwan	END-USER	Recombinant biologics
 基亞疫苗生物製劑股份有限公司 MEDIGEN VACCINE BIOLOGICS CO	Taipei / Taiwan	VACCINE / BIOLOGICS	Vaccines / biologics
 ADIMMUNE	Taichung	VACCINE / BIOLOGICS	Vaccines / biologics

CAPABILITY MIX

● End-user 1 ● CDMO / CRDMO 3 ● Vaccine / Biologics 2

07 INDIA

12 ENTRIES

India's biologics manufacturing landscape is particularly strong in biosimilars, vaccines, recombinant proteins, insulin, monoclonal antibodies and CDMO services.

COMPANY	MAJOR SITES / MANUFACTURING HUBS	MANUFACTURING TYPE	KEY CAPABILITIES
 Biocon	Bengaluru	END-USER	Biosimilar mAbs, insulin, recombinant proteins, DS/DP
 SERUM INSTITUTE OF INDIA	Pune	VACCINE / BIOLOGICS	Vaccines, recombinant proteins, biological products
 BHARAT BIOTECH	Hyderabad, Ankaleshwar, Mallur, Pune	VACCINE / BIOLOGICS	Vaccines, recombinant vaccines
 Biological E. Limited <i>Celebrating Life Every Day</i>	Hyderabad	VACCINE / BIOLOGICS	Vaccines, recombinant biologics
 zydus <i>Dedicated To Life</i>	Ahmedabad	END-USER	Biologics, biosimilars, vaccines
 INTAS	Ahmedabad	END-USER	Biosimilars, recombinant proteins, mAbs
 Syngene <i>Putting Science to Work</i>	Bengaluru	CDMO	Mammalian & microbial biologics
 ENZE NE <i>Biosciences Ltd.</i>	Pune	CDMO	Mammalian / microbial biologics
 AUROBINDO	Hyderabad	CDMO / END-USER	Large-scale biologics
 GLAND	Hyderabad	END-USER / CDMO	Sterile biologics / injectables
 WOCKHARDT	Aurangabad / Mumbai	BIOPHARMA	Vaccines / biologics
 Panacea Biotec <i>Innovation in support of life</i>	Baddi	VACCINE / BIOLOGICS	Vaccines / biological products

CAPABILITY MIX

● End-user 3

● CDMO / CRDMO 4

● Vaccine / Biologics 4

● Other 1

08 AUSTRALIA

6 ENTRIES

Australia's manufacturing base is smaller but strategically significant for vaccines, plasma-derived products, biologics, microbial manufacturing and pandemic preparedness.

COMPANY	MAJOR SITES / MANUFACTURING HUBS	MANUFACTURING TYPE	KEY CAPABILITIES
 Seqirus A CSL COMPANY	Tullamarine / Melbourne	VACCINE / BIOLOGICS	Cell-based influenza vaccines, Q fever, antivenoms
 CSL	Broadmeadows / Melbourne	END-USER	Plasma-derived biologics
 BioCina	Adelaide, Perth	CDMO	Microbial biologics, pDNA, mRNA, LNP, sterile DP
 Pfizer	Melbourne	END-USER	Pharmaceutical / biologics manufacturing
 Boehringer Ingelheim BIOXCCELLENCE	Melbourne	END-USER / CDMO	Biopharmaceutical manufacturing
 idt australia	Melbourne	CDMO	Sterile / biologics manufacturing

CAPABILITY MIX

● End-user 2 ● CDMO / CRDMO 3 ● Vaccine / Biologics 1

Where APAC goes next



APAC's biologics manufacturing landscape is evolving from a collection of regional production centres into an increasingly interconnected manufacturing ecosystem. Growing capacity, expanding CDMO networks and investment in advanced manufacturing technologies are creating new opportunities across the development-to-commercialisation value chain.

As manufacturers move toward greater flexibility, efficiency and resilience, the next phase of growth will depend not only on how much capacity is available, but also on how effectively facilities can adopt new technologies, optimise processes and respond to increasingly complex biologics pipelines.



The future of biologics manufacturing in APAC will be shaped by the convergence of capacity, technology, talent and strategic partnerships.



Biologics Manufacturing Asia 2027

Where APAC's Biologics Manufacturing Community Connects

23–24 March 2027 | Sands Expo & Convention Centre, Singapore
Part of Biopharma APAC Confex 2027

CO-LOCATED WITH

ADC Asia Congress
Clinical Trials Festival Asia
BioSupply Chain Asia
Cell & Gene Therapy World Asia
Oligos & Peptides World Asia

Where industry leaders meet, innovations connect and new opportunities take shape.

Meet leading biopharma professionals, explore new technologies and build valuable partnerships shaping the future of APAC biomanufacturing.

Connect. Discover. Partner.

JOIN AS

Delegate

Partner

Sponsor



IMAPAC
IMAGINE YOUR IMPACT

IMAPAC.COM